INTRODUCTION
Mucopolysaccharidosis type IIID (MPS IIID) or Sanfilippo syndrome type D is a lysosomal storage disorder caused by the deficiency of N-acetylglucosamine-6-sulphatase (Glc6S ; EC 3;1;6;14), a lysosomal hydrolase that desulphates the α-linked terminal N-acetylglucosamine 6-sulphate residue at the nonreducing end of heparan sulphate [1, 2] . The MPS IIID clinical phenotype is characterized by progressive and severe mental retardation, behavioural problems, degeneration of the central nervous system and mild visceral and skeletal involvement [2] . Human Glc6S has been purified from urine and liver [3] [4] [5] , the cDNA cloned and the chromosomal location of the gene identified [6, 7] .
Recently, a Nubian goat (Capra aegagrus) with this disorder has been described [8] , and an MPS IIID goat colony was established. The caprine Glc6S cDNA was subsequently cloned [9] and the molecular defect in the MPS IIID goat was identified as an R102X nonsense mutation [10] . The MPS IIID goat displayed clinical features consistent with a severe phenotype, and biochemical analysis indicated that the type and distribution of storage materials within goat tissues were comparable with those observed in human MPS IIID (M. Z. Jones, unpublished work). The clinical and biochemical similarity between human and goat MPS IIID suggests that the goat will be a relevant animal model of the human Sanfilippo syndromes. Currently, it is the only available animal model for any of the four MPS III subtypes.
Abbreviations used : GlcNAc6SIdOA, O-(α-N-acetylglucosamine 6-sulphate)-(1 3)-L- [6- 3 H]idonic acid ; EFlα, elongation factor-1α ; rcGlc6S, recombinant caprine N-acetylglucosamine-6-sulphatase ; COON'S/DMEM, COON'S Dulbecco's modified Eagle's medium ; MPS, mucopolysaccharidosis ; CHO-K1 cells, Chinese hamster ovary cells ; M6P, mannose 6-phosphate ; DTT, dithiothreitol ; BME, basal medium Eagle's ; FCS, fetal calf serum ; PSK, penicillin, streptomycin, kanamycin ; 4MUS, 4-methylumbelliferyl sulphate ; 4MU-α-GlcNAc6S, 4-methylumbelliferyl-α-D-Nacetylglucosaminide-6-sulphate ; G418, Geneticin. 1 To whom correspondence should be addressed.
isolated. One clone, CHOrcGlc6S.17, which secreted the highest Glc6S activity into the culture medium, was selected and cultured in cell factories. The secreted recombinant cGlc6S (rcGlc6S) precursor was purified to homogeneity from conditioned medium by a two-column procedure which consisted of a Cu# + -chelating Sepharose column followed by TSK G3000SW gel filtration. The native molecular mass of rcGlc6S was estimated to be 102 kDa and the subunit size was 94 kDa. The kinetic properties of cGlc6S were similar to those of human Glc6S isolated from liver. rcGlc6S was endocytosed by fibroblasts from patients with mucopolysaccharidosis type IIID via the mannose 6-phosphate receptor-mediated pathway resulting in correction of the storage phenotype of these cells.
In MPS III, a major site of pathology is neuronal tissue, especially the brain. Studies of bone marrow transplantation and enzyme replacement therapy in animal models of lysosomal storage disorders have shown that delivery of sufficient enzyme to the brain is hindered by the blood-brain barrier [11] [12] [13] [14] . Therefore, in order to facilitate enzyme-replacement therapy for MPS IIID, purified recombinant caprine (rcGlc6S) may require chemical modification to increase uptake into the brain.
As a first step towards enzyme-replacement therapy for goat (and eventually human) MPS IIID, the aim of this work was to develop a scheme for the production and purification of active rcGlc6S in a form that will be efficiently targeted to tissues at sites of pathology. In this study, we report the expression of the full-length cGlc6S cDNA in CHO cells, the purification of the secreted precursor form of cGlc6S by a two-column procedure and its physical and catalytic properties. We also demonstrate the enzymic correction of human MPS IIID skin fibroblasts mediated by the mannose 6-phosphate (M6P) receptor pathway.
MATERIALS AND METHODS

Materials
Restriction endonucleases and other enzymes for DNA manipulation were purchased from Boehringer-Mannheim (Dulwich, SA, Australia) and New England Biolabs (Beverly, MA, U.S.A.). DNA oligonucleotides were synthesized with a PCR-mate EP (Gaithersburg, MD, U.S.A.). Pluronic F68 was purchased from Fluka (Buchs, Switzerland). The ultrafiltration stirred-cell (model 8200) and Diaflo ultrafiltration membrane YM10 were from Amicon (Danvers, MA, U.S.A.). Dimethylglutarate, dithiothreitol (DTT), butyric acid, 4-methylumbelliferyl sulphate (4MUS) and BSA were obtained from Sigma (St. Louis, MO, U.S.A.). T4 polynucleotide kinase, Chelating Sepharose (fast flow), high-and low-molecular-mass standard kits for SDS\ PAGE and gel chromatography were purchased from Pharmacia (North Ryde, NSW, Australia). 4-Methylumbelliferyl-α--Nacetylglucosaminide-6-sulphate (4MU-α-GlcNAc6S) was from Moscerdam (Rotterdam, The Netherlands). TSK G3000SW Ultrapac was purchased from LKB (Bromma, Sweden). Na # $&SO % (2 mCi\mmol) was obtained from New England Nuclear (Du Pont, North Ryde, NSW, Australia).
DNA manipulation
All DNA manipulations were standard techniques [15] . The fulllength Glc6S cDNA was assembled from 5h and 3h sequences [9] (K. Friderici, unpublished work). The 5h sequence was obtained from clone 1-1, an 890 bp cDNA PCR product derived from goat brain RNA containing 18 bp of 5h non-coding sequence and the first approximately 870 bp of cGlc6S coding sequence, subcloned into the pCRII vector (Invitrogen, San Diego, CA, U.S.A.). The 3h sequence was obtained from clone 2-1, a 1n23 kb EcoRI cDNA fragment in pBluescript containing nt 553 to nt 1694 of the cGlc6S coding region and 93 bp of 3h non-coding sequence. Clone 2-1 was isolated from a custom-made λZAP caprine kidney cDNA library [9] . The expression vector pEFNeo has been described previously [16] .
CHO cell transfection
The cGlc6S cDNA expression construct in pEFNeo ( Figure 1 ) was electroporated into CHO cells using a Cell-Porator, as previously described [17] . Stably transfected cells were selected with G418 (750 µg\ml total mass).
CHO cell culture
CHO-K1 cells were grown in COON'S\DMEM supplemented with 10 % (v\v) FCS, 0n1 % (w\v) Pluronic F68 and antibiotics PSK (100 µg\ml penicillin, 100 µg\ml streptomycin sulphate, 120 µg\ml kanamycin sulphate) at 37 mC in a 5% CO # \air atmosphere. When the cells reached confluency, the cell monolayers were thoroughly rinsed with PBS and the medium was replaced with FCS-free COON'S\DMEM supplemented with 0n1 % (w\v) Pluronic F68 and PSK. In order to increase the yield of rcGlc6S, 1 mM butyric acid and 10 mM NH % Cl were added to the medium. Cells were cultured in 75 cm# culture flasks or in cell factories (1200 cm# two-layer system) at 37 mC typically for 4-5 days between changes of medium.
Purification of rcGlc6S
The rcGlc6S was purified from the conditioned medium using a two-column procedure. The CHOrcGlc6S-conditioned medium was clarified by centrifugation (750 g for 10 min), the supernatant filtered through 0n2 µm filter units (Sartorius, Go$ ttingen, Germany) and the filtrate was stored at 4 mC. Batches of filtered conditioned medium were concentrated and dialysed against buffer A [15 mM sodium dimethylglutarate, 10 % (v\v) glycerol, 0n1 mM DTT, 3 mM NaN $ , pH 6n0] using Amicon stirred-cell ultrafiltration units with Diaflo YM10 membranes. All procedures were performed at 4 mC unless otherwise stated.
Chelating Sepharose (fast flow) (10 cmi1 cm column) was complexed with Cu# + cations and equilibrated with buffer B [15 mM sodium dimethylglutarate, 500 mM NaCl, 10 mM Tris\HCl, 10 % (w\v) glycerol, 0n1 mM DTT, 3 mM NaN $ , pH 6n0]. The concentrated and dialysed CHOrcGlc6S-conditioned medium was adjusted to the composition of buffer B but at pH 7n0, and applied to the Cu# + -chelating Sepharose column (flow rate 0n5 ml per min). The column was first washed with 15 ml of buffer B at pH 7n0 and then with successive 14 ml batches of buffer B of decreasing pH (pH 5n0, 4n8, 4n6, 4n45, 4n2, 4n0, 3n8). The column was then washed with 10 ml of 1 M NaCl\100 mM EDTA, pH 8n0, which chelates Cu# + ions and consequently elutes any remaining bound proteins from the column. Each eluate was collected into 2 ml of 1 M dimethylglutarate pH 7n0. Fraction samples were dialysed against buffer A at 4 mC overnight. Aliquots (5 µl) of dialysed samples were assayed for Glc6S activity using the fluorogenic substrate 4MU-α-GlcNAc6S (see below), and total protein was determined.
Fractions containing Glc6S activity (pH 5n0 and 4n8) were pooled ( Figure 2a ) and concentrated in an Amicon ultrafiltration stirred-cell. A 200 µl sample of the concentrated pool was applied to a TSK G3000SW Ultrapac column (30 cmi0n8 cm) which was equilibrated in 15 mM dimethylglutarate\0n5 M NaCl\3 mM NaN $ , pH 6n0 (flow rate 0n5 ml\min and a pressure of 150 kPa). Native molecular mass was determined using the above FPLC system which was calibrated with molecular-mass standards as described previously [18] . A sample from the fraction with peak 
Glc6S assays
Three different assays were used to determine Glc6S activity. The first utilized the fluorogenic substrate 4MU-α-GlcNAc6S and was performed as described by He et al. [20] , except that the first incubation of the two-step assay was at 37 mC for 14n5 h. Glc6S was also assayed using the radiolabelled disaccharide substrate GlcNAc6SIdOA [4, 5] as follows ; the total assay volume of 12 µl included 1 µl of 17 µM GlcNAc6SIdOA, 3 µl of 0n1 M dimethylglutarate pH 6n0, 1 µl of BSA (6 mg\ml) and 1 µl of enzyme sample either diluted in 25 mM dimethylglutarate, pH 6n0, or dialysed against 5 mM sodium acetate pH 4n0. The assay volume was made up to 12 µl with water. Assay tubes were incubated at 37 mC for the appropriate time to give between 10 and 30 % breakdown of substrate to product. High-voltage electrophoresis was used to separate substrate from product [4] . The fluorogenic substrate 4MUS was also used to assay rcGlc6S under conditions of 5 mM 4MUS, 50 mM sodium acetate, pH 5n2, and BSA (50 µg\ml) in a total volume of 110 µl. The first assay was used to measure Glc6S activity in culture medium and partially purified fraction samples, and the second and third assays were used to measure activity in purified fractions.
Assay of other lysosomal enzymes
β-Hexosaminidase was assayed with 4-methylumbelliferyl 2-acetamido-deoxy-β--glucopyranoside [21] . Iduronate-2-sulphatase [18] , α--iduronidase [22] , N-acetylgalactosamine-4-sulphatase [23] , N-acetylgalactosamine-6-sulphatase [24] , sulphamidase [25] and glucuronate-2-sulphatase [26] were assayed by previously published procedures.
Protein assay
Total protein was determined using either the Lowry method [27] or the Bio-Rad protein assay kit according to the manufacturer's instructions, using BSA as the standard.
Correction of human MPS IIID fibroblasts
Fibroblasts from two normal individuals (SF4292 and SF4294) and from a clinically severe MPS IIID patient (SF1941), who had undetectable levels of Glc6S activity in both fibroblasts and leucocytes, were grown to confluency in 25 cm# flasks in basal medium Eagle's (BME)\10 % (v\v) FCS and antibiotics PS (penicillin and streptomycin sulphate). Before labelling of fibroblasts with Na # $&SO % , the medium was removed, the cells rinsed with Ham's F12\10 % (v\v) FCS and penicillin only and re-fed with 3 ml\flask of the same medium to deplete the SO % #-pools. After 4 h, the medium was replaced with fresh medium [Ham's F12\10 % (v\v) FCS and penicillin] supplemented with Na # $&SO % at 10 µCi\ml. After 48 h the cells were rinsed with PBS and the medium changed to BME\10 % (v\v) FCS and PS, and rcGlc6S was added at 0n5 and 5n0 µg\ml in the presence or absence of M6P (5 mM final concentration). Cells were harvested 48 h later by trypsin treatment, and washed three times with 0n15 M NaCl by centrifugation (750 g, 5 min)\resuspension. Cell pellets were resuspended in 100 µl of 20 mM Tris\HCl, 0n25 M NaCl, pH 7n0, the cells frozen and thawed six times and the cell lysates clarified by microcentrifugation (13 000 g ; 5 min; 4 mC). Cell lysates were dialysed against 5 mM sodium acetate, pH 4n0, overnight at 4 mC before being assayed for Glc6S and β-hexosaminidase activities, protein content and radioactivity.
Kinetics
Kinetic data (K m , V max and pH optimum) for Glc6S were obtained from Lineweaver-Burk plots using the radiolabelled substrate and 4MUS. The assays were performed within a concentration ranged of 3n3-17 µM for the disaccharide substrate and 0n5-5 mM for 4MUS.
RESULTS AND DISCUSSION
Assembly of Glc6S expression construct
The full-length cGlc6S cDNA was assembled from two fragments before insertion into the expression vector. The 5h sequence of the cGlc6S cDNA was excised from clone 1-1 as a 0n6 kb XhoI-EcoRI fragment and contained 18 bp of 5h non-coding sequence and 552 bp of 5h coding sequence. The XhoI-EcoRI fragment was subcloned into the corresponding sites of the cloning vector pGEM7Zf(j) to generate pGEM-5hcGlc6S.1. The 3h sequence of the cGlc6S cDNA was excised as a 1n23 kb EcoRI fragment from clone 2-1 and contained nt 553 to nt 1694 of the cGlc6S coding region and 93 bp of 3h non-coding sequence. The 1n23 kb EcoRI fragment was then subcloned into the EcoRI site of pGEM-5hcGlc6S.1, and clones with the correct orientation of the 5h and 3h cGlc6S cDNA sequences were identified by restriction analysis. Clone pGEM-cGlc6S.8 was selected and the complete cGlc6S cDNA was excised from the polylinker as an approx. 1n8 kb XbaI(5h)-ClaI(3h) fragment.
The expression vector pEFNeo-EXCN.1 was constructed by linearizing pEFNeo with EcoRI and NotI and then inserting a pair of adaptor linkers containing EcoRI, XbaI, ClaI and NotI restriction sites (5h 3h). The full-length cGlc6S cDNA XbaI-ClaI fragment was then ligated into the corresponding sites of pEFNeo-EXCN.1 to generate pEF-cGlc6S.3 ( Figure 1) .
In pEF-cGlc6S.3, the cGlc6S cDNA is under the transcriptional control of the human polypeptide chain elongation factor (EF1α) promoter. The expression vector also contained the human growth hormone polyadenylation signal and the genes for ampicillin and neomycin resistance.
6S expression in CHO cells
The Glc6S expression construct pEF-cGlc6S.3 was introduced into CHO-K1 cells by electroporation, and stably transfected clonal lines were isolated by G418 selection. In order to select the clone secreting the highest levels of cGlc6S activity into the culture medium, 39 clonal CHO lines were individually cultured to confluence, and Glc6S activity was assayed in the medium using 4MU-α-GlcNAc6S [20] .
The highest activity clone, CHOrcGlc6S.17, was found to secrete 32-fold higher Glc6S activity into the culture medium relative to untransfected CHO-K1 (results not shown). Preliminary experiments confirmed that the addition of butyric acid and NH % Cl increased the yield of Glc6S activity in conditioned medium (results not shown). NH % Cl causes the rerouting of lysosomally destined enzymes to the secretory pathway [28] . Butyric acid was added because it has been shown to increase expression of transfected genes [29] .
Large-scale production and purification of rcGlc6S
Clone CHOrcGlc6S.17 was expanded and cultured in a cell factory system as described in Materials and methods. The yield of rcGlc6S secreted into the medium was about 5 mg\litre (range 2-7 mg) or 3-4 % of total medium protein, based on Coomassie staining of bands on SDS\PAGE (results not shown). Recombinant cGlc6S was purified to homogeneity from the culture medium of CHOrcGlc6S.17 using a two-column procedure consisting of Cu# + -chelating Sepharose and gel filtration.
All the rcGlc6S applied to the Cu# + -chelating column at pH 7n0 was bound and required a drop in pH for elution. The majority of rcGlc6S activity was eluted at pH 5 and pH 4n8, but activity was not completely eluted until pH 3n8. Fractions at pH 5n0 and 4n8, which together contained approx. 20 % of the total activity applied to the column (Figure 2a) , were pooled, concentrated and dialysed. The majority of the contaminating protein was in the EDTA elution (33 %), which also contained some activity (" 2 %). The original flow-through had 5 % of the initial contaminating proteins.
SDS\PAGE of the pooled fractions from the Cu# + -chelating Sepharose step indicated a major protein band at 94 kDa with a few minor-molecular-mass species between 43 kDa and 67 kDa. These contaminants were successfully removed by gel filtration on TSKG3000SW as shown in Figure 3 . The faint bands observed at apparent molecular masses of approx. 54 and 62 kDa in purified cGlc6S were also present in the molecular-mass standards lane and also in a buffer-only lane (results not shown) and therefore were considered to be artifacts of SDS\PAGE and not contaminants within the cGlc6S preparation. Recovery of cGlc6S activity from this step was 30 % of the activity loaded. The overall recovery of rcGlc6S from medium after the two-column purification was relatively low. Higher yields may be obtained by pooling pH eluates in addition to fractions pH 5n0 and 4n8 from the Cu# + -chelating Sepharose column.
When a sample from fraction 20 was submitted to SDS\PAGE under reducing conditions, there was one major band at 94 kDa ( Figure 3 ). cGlc6S has 13 potential N-glycosylation sites, and, as the molecular mass of cGlc6S deduced from the amino acid sequence derived from the cGlc6S cDNA is 57n7 kDa, it would appear that most, if not all, are utilized. The 36 kDa difference between the core protein mass and the precursor molecular mass is presumably due to oligosaccharide chains. The diffuseness of the band was considered to be due to heterogeneity in the Nlinked oligosaccharides and has been observed in other recombinant enzymes [16] . The oligosaccharide content of the precursor was indirectly confirmed by the observation that rcGlc6S bound strongly to concanavalin A-Sepharose (results not shown).
Mature Glc6S isolated from human liver comprises several forms [4, 7] . The two major forms are a form-A polypeptide with a single subunit of molecular mass 78 kDa and a form B consisting of two non-disulphide-linked subunits derived from the proteolytic processing of form A to a 32 kDa N-terminal and 48 kDa C-terminal species.
The majority of lysosomal enzyme precursors undergo a series of post-translational ' maturation ' modifications such as limited endo-and exo-proteolytic cleavage and partial trimming of oligosaccharide side chains during transit through the prelysosomal organelles and residence in the lysosome [30] . Lysosomal enzyme precursors can also be secreted extracellularly via an alternative pathway in which these maturation processes are absent or reduced. High-level expression of lysosomal enzymes in cell culture favours the secretion of lysosomal enzymes, and consequently precursor forms predominate in the medium. Therefore the rcGlc6S species purified from conditioned medium is a precursor form that has not undergone the maturation process characteristic of enzymes in transit to the lysosome. After gel filtration, rcGlc6S was free of detectable amounts of other lysosomal enzymes including iduronate-2-sulphatase, α--iduronidase, N-acetylgalactosamine-4-sulphatase, glucuronate-2-sulphatase, sulphamidase and N-acetylgalactosamine-6-sulphatase (results not shown).
Kinetics of rcGlc6S
Kinetic data (Table 1) indicate that both rcGlc6S and the mature form of Glc6S isolated from human liver have the same order of magnitude K m , V max and pH optima with respect to the disaccharide substrate. Results with 4MUS (Table 2) demonstrate that Glc6S, although not an arylsulphatase, is capable of binding 4MUS but its rate of substrate turnover is 4800 times slower than recombinant human N-acetylgalactosamine-4-sulphatase which is an arylsulphatase. This has been observed with other nonarylsulphatases such as recombinant human iduronate-2-sulphatase and N-acetylgalactosamine-6-sulphatase [24] and with mature human Glc6S purified from liver [7] .
Enzymic correction of MPS IIID fibroblasts
MPS IIID skin fibroblasts (SF1941) cultured in the presence of purified rcGlc6S at 0n5 µg\ml showed a level of Glc6S activity comparable with that seen in normal control skin fibroblasts, and this was elevated approximately 3-fold above normal levels when 10-fold the enzyme concentration was used ( 
achieved as this storage was corrected by uptake of Glc6S activity. Interestingly, even at very low levels of enzyme (as seen in fibroblasts treated with M6P) there is sufficient enzyme taken up by these cells to correct the storage phenotype. The 2-fold increase in storage in human MPS IIID cells relative to normals, although not large, was identical with that observed in caprine MPS IIID cells relative to normals [8] .
Conclusion
In this paper, we have successfully expressed rcGlc6S in CHO culture and purified the precursor form from conditioned medium using a two-column procedure. The kinetic properties of the rcGlc6S precursor (K m , V max and pH optima) were similar to the mature form A of human Glc6S purified from liver, with respect to the disaccharide substrate. The rcGlc6S precursor was taken up by cultured cells via the M6P receptor-mediated pathway and efficiently corrected lysosomal storage in human MPS IIID cells. A major site of pathology in MPS III is neuronal tissue, in particular the brain. The blood-brain barrier, however, prevents uptake of exogenous enzymes from the circulation. The availability of large quantities of the rcGlc6S precursor will facilitate the investigation of modifications to the enzyme in an effort to increase transport across the blood-brain barrier. Such modifications may include the addition of polylysine, treatment with ethylenediamine or linking the enzyme to insulin fragments [31] . The effect of modifications of rcGlc6S on transport to sites of pathology can then be appropriately evaluated in the MPS IIID goat model.
